High Grade Serous Ovarian Cancer research hub

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

This study looks at combining two drugs, Idetrexed and olaparib, to treat a type of ovarian cancer (high-grade serous) that hasn't responded to usual treatments. The goal is to see if this combination can target cancer cells more effectively.

An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)